A new study led by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center, situated in Scottsdale Healthcare proves that researchers can offer treatment by using the latest advances in genomic sequencing for every patient with cancer that develops rapidly. This study was published in the scientific journal PLOS ONE and shows that this therapeutic method focuses on blocking the progression of cancer.
The study`s lead author is Dr. Glen Weiss, an Associate Professor in TGen`s Cancer and Cell Biology Division. One of the senior authors of this study is Dr. Daniel Von Hoff, TGen Distinguished Professor and Physician in Chief; Chief Scientific Officer for the Virginia G. Piper Cancer Center Clinical Trials.
According to Dr. John Carpten, TGen Deputy Director and a senior of the study, “even during the relatively short time that this study was enrolling, we observed significant improvements in sequencing analyses and lower costs”. In this study also participated Franklin C. Salisbury Jr., NFCR President.
No comments:
Post a Comment